Attached files

file filename
8-K - 8-K - Merck & Co. Inc.a13-4074_18k.htm
EX-99.1 - EX-99.1 - Merck & Co. Inc.a13-4074_1ex99d1.htm

Exhibit 99.2

 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2012

 

2011

 

% Change

 

 

 

1Q

 

2Q

 

3Q

 

4Q

 

Full Year

 

1Q

 

2Q

 

3Q

 

4Q

 

Full Year

 

4Q

 

Full Year

 

Sales

 

$

11,731

 

$

12,311

 

$

11,488

 

$

11,738

 

$

47,267

 

$

11,580

 

$

12,151

 

$

12,022

 

$

12,294

 

$

48,047

 

-5

%

-2%

 

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

4,037

 

4,112

 

4,137

 

4,160

 

16,446

 

4,059

 

4,284

 

4,352

 

4,176

 

16,871

 

 

-3%

 

 

Marketing and administrative

 

3,074

 

3,249

 

3,063

 

3,390

 

12,776

 

3,164

 

3,525

 

3,340

 

3,704

 

13,733

 

-8

%

-7%

 

 

Research and development

 

1,862

 

2,165

 

1,918

 

2,224

 

8,168

 

2,158

 

1,936

 

1,954

 

2,419

 

8,467

 

-8

%

-4%

 

 

Restructuring costs

 

219

 

144

 

110

 

191

 

664

 

(14

)

668

 

119

 

533

 

1,306

 

-64

%

-49%

 

 

Equity income from affiliates

 

(110

)

(142

)

(158

)

(231

)

(642

)

(138

)

(55

)

(161

)

(257

)

(610

)

-10

%

5%

 

 

Other (income) expense, net

 

142

 

103

 

200

 

176

 

623

 

622

 

121

 

66

 

139

 

946

 

27

%

-34%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Taxes

 

2,507

 

2,680

 

2,218

 

1,828

 

9,232

 

1,729

 

1,672

 

2,352

 

1,580

 

7,334

 

16

%

26%

 

 

Income Tax Provision (Benefit)

 

740

 

860

 

455

 

385

 

2,440

 

658

 

(382

)

628

 

37

 

942

 

 

 

 

 

 

Net Income

 

1,767

 

1,820

 

1,763

 

1,443

 

6,792

 

1,071

 

2,054

 

1,724

 

1,543

 

6,392

 

-6

%

6%

 

 

Less: Net Income Attributable to Noncontrolling Interests

 

29

 

27

 

34

 

42

 

131

 

28

 

30

 

32

 

31

 

120

 

 

 

 

 

 

Net Income Attributable to Merck & Co., Inc.

 

$

1,738

 

$

1,793

 

$

1,729

 

$

1,401

 

$

6,661

 

$

1,043

 

$

2,024

 

$

1,692

 

$

1,512

 

$

6,272

 

-7

%

6%

 

 

Earnings per Common Share Assuming Dilution

 

$

0.56

 

$

0.58

 

$

0.56

 

$

0.46

 

$

2.16

 

$

0.34

 

$

0.65

 

$

0.55

 

$

0.49

 

$

2.02

 

-6

%

7%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Shares Outstanding Assuming Dilution

 

3,074

 

3,072

 

3,079

 

3,074

 

3,076

 

3,104

 

3,110

 

3,091

 

3,069

 

3,094

 

 

 

 

 

 

Tax Rate

 

29.5

%

32.1

%

20.5

%

21.1

%

26.4

%

38.1

%

-22.8

%

26.7

%

2.3

%

12.8

%

 

 

 

 

 

 

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

 



 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FOURTH  QUARTER 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2c

 

 

 

GAAP

 

Acquisition-
Related Costs 
(1)

 

Restructuring
Costs 
(2)

 

Certain Other
Items

 

Adjustment
Subtotal

 

Non-GAAP

 

Sales

 

$

12,294

 

 

 

 

 

 

 

$

 

$

12,294

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

4,176

 

1,212

 

68

 

7

 

1,287

 

2,889

 

Marketing and administrative

 

3,704

 

86

 

42

 

 

 

128

 

3,576

 

Research and development

 

2,419

 

244

 

49

 

 

 

293

 

2,126

 

Restructuring costs

 

533

 

 

 

533

 

 

 

533

 

 

Equity income from affiliates

 

(257

)

 

 

 

 

 

 

 

(257

)

Other (income) expense, net

 

139

 

(63

)

 

 

(1

)

(64

)

203

 

Income Before Taxes

 

1,580

 

(1,479

)

(692

)

(6

)

(2,177

)

3,757

 

Taxes on Income

 

37

 

 

 

 

 

 

 

(711

)(3)

748

 

Net Income

 

1,543

 

 

 

 

 

 

 

(1,466

)

3,009

 

Less: Net Income Attributable to Noncontrolling Interests

 

31

 

 

 

 

 

 

 

 

31

 

Net Income Attributable to Merck & Co., Inc.

 

$

1,512

 

 

 

 

 

 

 

$

(1,466

)

$

2,978

 

Earnings per Common Share Assuming Dilution

 

$

0.49

 

 

 

 

 

 

 

 

 

$

0.97

(4)

Average Shares Outstanding Assuming Dilution

 

3,069

 

 

 

 

 

 

 

 

 

3,069

 

Tax Rate

 

2.3

%

 

 

 

 

 

 

 

 

19.9

%

 

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions.  Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company’s formal restructuring programs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.  Amounts included in other (income) expense, net reflect the favorable resolution of certain reserves assumed in conjunction with mergers and acquisitions.

 

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

 

(3) Includes the favorable impact of certain state tax rate changes that resulted in a net $40 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

 

(4) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders.  Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,973 million for the fourth quarter of 2011.

 



 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FULL YEAR 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2d

 

 

 

GAAP

 

Acquisition-
Related Costs 
(1)

 

Restructuring
Costs 
(2)

 

Certain Other
Items 
(3)

 

Adjustment
Subtotal

 

Non-GAAP

 

Sales

 

$

48,047

 

 

 

 

 

 

 

$

 

$

48,047

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

16,871

 

5,137

 

348

 

7

 

5,492

 

11,379

 

Marketing and administrative

 

13,733

 

278

 

119

 

 

 

397

 

13,336

 

Research and development

 

8,467

 

587

 

138

 

 

 

725

 

7,742

 

Restructuring costs

 

1,306

 

 

 

1,306

 

 

 

1,306

 

 

Equity income from affiliates

 

(610

)

 

 

 

 

 

 

 

(610

)

Other (income) expense, net

 

946

 

(63

)

 

 

235

 

172

 

774

 

Income Before Taxes

 

7,334

 

(5,939

)

(1,911

)

(242

)

(8,092

)

15,426

 

Taxes on Income

 

942

 

 

 

 

 

 

 

(2,667

)(4)

3,609

 

Net Income

 

6,392

 

 

 

 

 

 

 

(5,425

)

11,817

 

Less: Net Income Attributable to Noncontrolling Interests

 

120

 

 

 

 

 

 

 

 

120

 

Net Income Attributable to Merck & Co., Inc.

 

$

6,272

 

 

 

 

 

 

 

$

(5,425

)

$

11,697

 

Earnings per Common Share Assuming Dilution

 

$

2.02

 

 

 

 

 

 

 

 

 

$

3.77

(5)

Average Shares Outstanding Assuming Dilution

 

3,094

 

 

 

 

 

 

 

 

 

3,094

 

Tax Rate

 

12.8

%

 

 

 

 

 

 

 

 

23.4

%

 

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect expenses of $5.0 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as $118 million of impairment charges on product intangibles.  Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company’s formal restructuring programs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.  Amounts included in other (income) expense, net reflect the favorable resolution of certain reserves assumed in conjunction with mergers and acquisitions.

 

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

 

(3) Included in other (income) expense, net is a $500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson,  a $136 million gain on the divestiture of the company’s interest in the Johnson & JohnsonºMerck Consumer Pharmaceuticals Company joint venture and a $127 million gain on the sale of certain manufacturing facilities and related assets.

 

(4) Includes a net benefit of approximately $700 million relating to the settlement of the company’s 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $270 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

 

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders.  Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $11,670 million for the full year of 2011.

 



 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FOURTH QUARTER 2012

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3a

 

 

 

Global

 

U.S.

 

International

 

 

 

4Q12

 

4Q11

 

% Change

 

4Q12

 

4Q11

 

% Change

 

4Q12

 

4Q11

 

% Change

 

TOTAL SALES (1)

 

$

11,738

 

$

12,294

 

-5

 

$

4,716

 

$

5,296

 

-11

 

$

7,022

 

$

6,998

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PHARMACEUTICAL

 

10,085

 

10,755

 

-6

 

3,915

 

4,606

 

-15

 

6,170

 

6,149

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Primary Care and Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zetia

 

676

 

640

 

6

 

345

 

327

 

5

 

331

 

313

 

6

 

Vytorin

 

435

 

475

 

-8

 

186

 

213

 

-13

 

249

 

262

 

-5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diabetes & Obesity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Januvia

 

1,134

 

960

 

18

 

565

 

503

 

13

 

568

 

457

 

24

 

Janumet

 

452

 

386

 

17

 

237

 

193

 

23

 

215

 

193

 

12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Respiratory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Singulair

 

480

 

1,461

 

-67

 

25

 

957

 

-97

 

456

 

504

 

-10

 

Nasonex

 

308

 

325

 

-5

 

138

 

163

 

-16

 

169

 

161

 

5

 

Dulera

 

67

 

37

 

83

 

64

 

36

 

79

 

2

 

1

 

*

 

Clarinex

 

56

 

129

 

-57

 

4

 

51

 

-93

 

52

 

78

 

-33

 

Asmanex

 

44

 

57

 

-23

 

38

 

51

 

-24

 

5

 

6

 

-10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Women’s Health & Endocrine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NuvaRing

 

164

 

168

 

-2

 

99

 

102

 

-3

 

66

 

66

 

 

Fosamax

 

154

 

211

 

-27

 

6

 

8

 

-24

 

148

 

204

 

-27

 

Follistim AQ

 

116

 

126

 

-8

 

42

 

42

 

-1

 

75

 

84

 

-11

 

Implanon

 

94

 

74

 

27

 

35

 

33

 

4

 

59

 

40

 

46

 

Cerazette

 

68

 

69

 

-1

 

 

 

 

 

 

 

68

 

69

 

-1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maxalt

 

162

 

178

 

-9

 

128

 

132

 

-3

 

34

 

46

 

-27

 

Arcoxia

 

115

 

110

 

5

 

 

 

 

 

 

 

115

 

110

 

5

 

Avelox

 

55

 

95

 

-42

 

52

 

86

 

-40

 

3

 

9

 

-68

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital and Specialty

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Immunology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remicade

 

549

 

511

 

8

 

 

 

 

 

 

 

549

 

511

 

8

 

Simponi

 

95

 

61

 

56

 

 

 

 

 

 

 

95

 

61

 

56

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Infectious Disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Isentress

 

381

 

387

 

-2

 

214

 

193

 

11

 

167

 

194

 

-14

 

Cancidas

 

145

 

164

 

-11

 

9

 

12

 

-24

 

136

 

152

 

-10

 

PegIntron

 

143

 

175

 

-18

 

8

 

25

 

-67

 

134

 

150

 

-10

 

Invanz

 

116

 

110

 

6

 

61

 

55

 

10

 

55

 

54

 

2

 

Victrelis

 

115

 

87

 

32

 

52

 

58

 

-10

 

63

 

29

 

*

 

Primaxin

 

83

 

119

 

-30

 

4

 

14

 

-73

 

80

 

104

 

-24

 

Noxafil

 

68

 

59

 

15

 

20

 

16

 

24

 

47

 

42

 

12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Temodar

 

229

 

230

 

-1

 

101

 

99

 

3

 

128

 

132

 

-3

 

Emend

 

131

 

114

 

16

 

74

 

68

 

9

 

57

 

46

 

25

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cosopt / Trusopt

 

113

 

117

 

-3

 

3

 

4

 

-10

 

110

 

113

 

-3

 

Bridion

 

75

 

60

 

26

 

 

 

 

 

 

 

75

 

60

 

26

 

Integrilin

 

51

 

57

 

-11

 

46

 

50

 

-9

 

5

 

7

 

-26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diversified Brands

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cozaar / Hyzaar

 

315

 

427

 

-26

 

12

 

20

 

-40

 

303

 

407

 

-25

 

Propecia

 

112

 

117

 

-4

 

29

 

36

 

-18

 

83

 

81

 

2

 

Zocor

 

98

 

111

 

-12

 

7

 

8

 

-11

 

90

 

103

 

-12

 

Claritin Rx

 

63

 

74

 

-15

 

 

 

 

 

 

 

63

 

74

 

-15

 

Remeron

 

57

 

59

 

-4

 

1

 

1

 

-10

 

56

 

58

 

-4

 

Proscar

 

56

 

52

 

7

 

2

 

1

 

24

 

54

 

51

 

7

 

Vasotec / Vaseretic

 

48

 

58

 

-17

 

 

 

 

 

 

 

48

 

58

 

-17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gardasil

 

442

 

274

 

61

 

304

 

202

 

51

 

138

 

72

 

91

 

ProQuad, M-M-R II and Varivax

 

306

 

276

 

11

 

283

 

243

 

16

 

22

 

33

 

-33

 

Zostavax

 

225

 

78

 

*

 

211

 

73

 

*

 

14

 

5

 

*

 

Pneumovax

 

208

 

222

 

-7

 

165

 

137

 

21

 

43

 

86

 

-50

 

RotaTeq

 

168

 

195

 

-14

 

136

 

162

 

-16

 

32

 

33

 

-1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Pharmaceutical (2)

 

1,113

 

1,064

 

5

 

209

 

232

 

-10

 

904

 

832

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANIMAL HEALTH

 

898

 

868

 

3

 

236

 

192

 

23

 

662

 

676

 

-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSUMER CARE

 

395

 

361

 

9

 

250

 

225

 

11

 

145

 

136

 

6

 

Claritin OTC

 

100

 

92

 

9

 

68

 

59

 

15

 

32

 

33

 

-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Revenues (3)

 

360

 

310

 

16

 

315

 

274

 

15

 

45

 

37

 

21

 

Astra

 

251

 

256

 

-2

 

251

 

256

 

-2

 

 

 

 

 

 

 

 

* 100% or greater

(1)    Only select products are shown.

(2)    Includes Pharmaceutical products not individually shown above.  Other Vaccines sales included in Other Pharmaceutical were $69 million and $62 million on a global basis for fourth quarter 2012 and 2011, respectively.

(3)    Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

 



 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

FULL YEAR 2012

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3b

 

 

 

Global

 

U.S.

 

International

 

 

 

Full Year
2012

 

Full Year
2011

 

% Change

 

Full Year
2012

 

Full Year
2011

 

% Change

 

Full Year
2012

 

Full Year
2011

 

% Change

 

TOTAL SALES (1)

 

$

47,267

 

$

48,047

 

-2

 

$

20,392

 

$

20,495

 

-1

 

$

26,875

 

$

27,552

 

-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PHARMACEUTICAL

 

40,601

 

41,289

 

-2

 

17,041

 

17,117

 

 

23,560

 

24,172

 

-3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Primary Care and Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zetia

 

2,567

 

2,428

 

6

 

1,332

 

1,223

 

9

 

1,235

 

1,205

 

2

 

Vytorin

 

1,747

 

1,882

 

-7

 

764

 

888

 

-14

 

983

 

994

 

-1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diabetes & Obesity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Januvia

 

4,086

 

3,324

 

23

 

2,136

 

1,824

 

17

 

1,950

 

1,499

 

30

 

Janumet

 

1,659

 

1,363

 

22

 

865

 

712

 

21

 

795

 

651

 

22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Respiratory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Singulair

 

3,853

 

5,479

 

-30

 

2,152

 

3,536

 

-39

 

1,701

 

1,942

 

-12

 

Nasonex

 

1,268

 

1,286

 

-1

 

597

 

604

 

-1

 

671

 

682

 

-2

 

Clarinex

 

393

 

621

 

-37

 

126

 

197

 

-36

 

267

 

424

 

-37

 

Dulera

 

207

 

96

 

*

 

199

 

94

 

*

 

8

 

2

 

*

 

Asmanex

 

185

 

206

 

-10

 

166

 

185

 

-10

 

19

 

21

 

-11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Women’s Health & Endocrine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fosamax

 

676

 

855

 

-21

 

28

 

45

 

-38

 

648

 

810

 

-20

 

NuvaRing

 

623

 

623

 

 

366

 

369

 

-1

 

257

 

254

 

1

 

Follistim AQ

 

468

 

530

 

-12

 

165

 

163

 

1

 

303

 

367

 

-17

 

Implanon

 

348

 

294

 

18

 

139

 

126

 

11

 

209

 

169

 

24

 

Cerazette

 

271

 

268

 

1

 

 

 

 

 

 

 

271

 

268

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maxalt

 

638

 

639

 

 

491

 

451

 

9

 

146

 

187

 

-22

 

Arcoxia

 

453

 

431

 

5

 

 

 

 

 

 

 

453

 

431

 

5

 

Avelox

 

201

 

322

 

-37

 

192

 

288

 

-33

 

9

 

34

 

-72

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital and Specialty

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Immunology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remicade

 

2,076

 

2,667

 

-22

 

 

 

 

 

 

 

2,076

 

2,667

 

-22

 

Simponi

 

331

 

264

 

25

 

 

 

 

 

 

 

331

 

264

 

25

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Infectious Disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Isentress

 

1,515

 

1,359

 

11

 

822

 

681

 

21

 

692

 

678

 

2

 

PegIntron

 

653

 

657

 

-1

 

87

 

71

 

22

 

565

 

586

 

-3

 

Cancidas

 

619

 

640

 

-3

 

32

 

44

 

-28

 

587

 

595

 

-1

 

Victrelis

 

502

 

140

 

*

 

267

 

98

 

*

 

234

 

43

 

*

 

Invanz

 

445

 

406

 

10

 

227

 

205

 

11

 

218

 

200

 

9

 

Primaxin

 

384

 

515

 

-25

 

21

 

87

 

-76

 

363

 

429

 

-15

 

Noxafil

 

258

 

230

 

13

 

75

 

61

 

23

 

184

 

169

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Temodar

 

917

 

935

 

-2

 

423

 

396

 

7

 

494

 

538

 

-8

 

Emend

 

489

 

419

 

17

 

276

 

239

 

16

 

213

 

180

 

18

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cosopt / Trusopt

 

444

 

477

 

-7

 

14

 

16

 

-16

 

430

 

461

 

-7

 

Bridion

 

261

 

201

 

30

 

 

 

 

 

 

 

261

 

201

 

30

 

Integrilin

 

211

 

230

 

-8

 

193

 

208

 

-7

 

18

 

22

 

-16

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diversified Brands

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cozaar / Hyzaar

 

1,284

 

1,663

 

-23

 

28

 

107

 

-74

 

1,256

 

1,555

 

-19

 

Propecia

 

424

 

447

 

-5

 

124

 

134

 

-7

 

300

 

313

 

-4

 

Zocor

 

383

 

456

 

-16

 

27

 

32

 

-17

 

356

 

423

 

-16

 

Claritin Rx

 

244

 

314

 

-22

 

 

 

 

 

 

 

244

 

314

 

-22

 

Remeron

 

232

 

241

 

-4

 

5

 

6

 

-21

 

227

 

234

 

-3

 

Proscar

 

217

 

223

 

-3

 

5

 

5

 

-13

 

212

 

218

 

-3

 

Vasotec / Vaseretic

 

192

 

231

 

-17

 

 

 

 

 

 

 

192

 

231

 

-17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gardasil

 

1,631

 

1,209

 

35

 

1,113

 

880

 

26

 

517

 

329

 

57

 

ProQuad, M-M-R II and Varivax

 

1,273

 

1,202

 

6

 

1,164

 

1,108

 

5

 

109

 

93

 

17

 

Zostavax

 

651

 

332

 

96

 

607

 

320

 

90

 

44

 

12

 

*

 

RotaTeq

 

601

 

651

 

-8

 

453

 

522

 

-13

 

148

 

129

 

15

 

Pneumovax

 

580

 

498